Liquid Biopsy Market to Reach $7.7 Bn by 2031 | AI Integration & Multi-Omics to Drive Growth – TMR analysis

The global Liquid Biopsy Market is experiencing significant growth, driven by increasing cancer prevalence, advancements in non-invasive diagnostic technologies, and the rising adoption of precision medicine. Valued at US$ 3.7 billion in 2022, the market is projected to expand at a compound annual growth rate (CAGR) of 8.8% from 2023 to 2031, reaching US$ 7.7 billion by the end of the forecast period.

Get Sample PDF Brochure from here:

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=22994

Market Overview

Liquid biopsy is a minimally invasive diagnostic technique used to detect cancer-related genetic mutations, monitor treatment response, and guide therapeutic decisions. Unlike traditional tissue biopsies, liquid biopsies use blood samples to analyze circulating tumor cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles, offering real-time insights into cancer progression and treatment efficacy.

“The increasing adoption of liquid biopsy is transforming oncology diagnostics by enabling early cancer detection, personalized treatment plans, and real-time disease monitoring,” said TMR Study.

Key Market Drivers

Several factors are fueling the expansion of the liquid biopsy market:

• Rising Cancer Incidence – The growing global burden of cancer is driving demand for non-invasive diagnostic solutions.
• Advancements in Genomics and Precision Medicine – Technological breakthroughs in next-generation sequencing (NGS) and polymerase chain reaction (PCR) techniques are enhancing the accuracy and efficiency of liquid biopsies.
• Non-Invasive and Real-Time Monitoring – Liquid biopsy provides a less painful, faster, and more comprehensive alternative to traditional tissue biopsy.
• Growing Adoption in Companion Diagnostics – The integration of liquid biopsy with targeted cancer therapies is improving treatment outcomes.
• Increased R&D Investments – Governments and private organizations are funding research to develop more advanced liquid biopsy technologies.

Recent Developments

• Guardant Health (2023) – Launched an AI-powered liquid biopsy platform for early cancer detection, improving accuracy and reducing false positives.
• Bio-Rad Laboratories (2023) – Introduced a high-sensitivity digital PCR-based liquid biopsy assay for monitoring minimal residual disease (MRD) in cancer patients.
• Roche Diagnostics (2023) – Expanded its liquid biopsy portfolio with a multi-cancer early detection test designed for population-wide screening.

Competitive Landscape

The liquid biopsy market is highly competitive, with major players focusing on technological advancements, strategic collaborations, and product innovations. Key industry leaders include:

• Biocept, Inc.
• MDxHealth
• Myriad Genetics, Inc.
• Bio-Rad Laboratories
• QIAGEN
• F. Hoffmann-La Roche Ltd.
• Thermo Fisher Scientific, Inc.,
• Genomic Health, Inc.
• Illumina, Inc.

Get A Full Report Analysis: https://www.transparencymarketresearch.com/liquid-biopsy-market.html   

Analyst Perspective

The liquid biopsy market is expected to grow in 2023, driven by the rising prevalence of cancer, expanding applications of liquid biopsy, and ongoing research aimed at improving its effectiveness compared to other diagnostic methods. Additionally, the growing demand for non-invasive early cancer detection is anticipated to boost the liquid biopsy market in the coming years.

Top companies in the liquid biopsy sector are working together to set industry standards and meet rigorous regulatory demands.

Future Outlook

The future of the liquid biopsy market is expected to be shaped by continued advancements in multi-cancer detection, AI-driven diagnostics, and expanded applications beyond oncology. As healthcare providers increasingly embrace non-invasive testing, liquid biopsy is poised to become a standard tool in precision medicine.

“The adoption of liquid biopsy is revolutionizing cancer diagnostics by enabling early-stage detection, real-time monitoring, and personalized treatment approaches”.

Market Segmentation

The liquid biopsy market is segmented based on application, circulating biomarker, and end-user to provide a comprehensive understanding of the industry landscape.

By Application

1. Oncology: Liquid biopsy is widely used for cancer detection, monitoring, and personalized treatment.
2. Non-Invasive Prenatal Testing (NIPT): Utilized for prenatal screening and genetic testing.
3. Transplant Diagnostics: Applied in organ transplant monitoring and rejection detection.
4. Others: Includes applications in infectious diseases and autoimmune disorders.

By Circulating Biomarker

1. Circulating Tumor Cells (CTCs): Used for detecting and analyzing cancer cells in the bloodstream.
2. Free Nucleic Acid: Includes circulating tumor DNA (ctDNA) and RNA for genetic analysis.
3. Extracellular Vesicles/Exosomes: Emerging biomarkers for disease diagnosis and monitoring.

By End-User

1. Hospital Pharmacies: Primary distribution channel for liquid biopsy tests and related products.
2. Retail Pharmacies: Increasingly used for over-the-counter and prescription-based tests.
3. Online Sales: Growing segment due to the convenience of direct-to-consumer testing kits.

Visit our report to discover essential insights and analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=22994

Regional Insights

• North America leads the market, driven by advanced healthcare infrastructure, high adoption of precision medicine, and increasing cancer research funding.
• Europe follows closely, with regulatory support and strong investments in oncology diagnostics contributing to market growth.
• Asia-Pacific is expected to witness the fastest growth due to rising cancer cases, increasing healthcare investments, and growing awareness of early cancer detection.

Browse More Trending Research Reports:

Cryotherapy Market is expected to grow at a CAGR of 9.3% from 2024 to 2034 and reach US$ 885.7 Mn by the end of 2034.

Thermal Cycler Market is projected to grow at a CAGR of 5.1% from 2024 to 2034 and reach more than US$ 1.7 Billion by the end of 2034.

About Transparency Market Research 

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Follow Us: LinkedIn| Twitter| Blog | YouTube